Michihiro Hidaka
Overview
Explore the profile of Michihiro Hidaka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
858
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shimoda K, Komatsu N, Matsumura I, Ikeda K, Hino M, Hidaka M, et al.
Int J Hematol
. 2024 Aug;
120(3):314-324.
PMID: 39110143
Momelotinib, an oral Janus kinase (JAK) 1/2 and activin A receptor type 1 inhibitor, improved symptoms, splenomegaly, and anemia in patients with myelofibrosis (MF). This sub-analysis of SIMPLIFY-1 evaluated the...
2.
Rai S, Kim W, Ando K, Choi I, Izutsu K, Tsukamoto N, et al.
Haematologica
. 2024 Jun;
109(10):3357-3362.
PMID: 38841789
No abstract available.
3.
Kameda T, Utsunomiya A, Otsuka N, Kubuki Y, Uchida T, Shide K, et al.
BMC Infect Dis
. 2024 Jan;
24(1):96.
PMID: 38233756
Background: Whether human T-lymphotropic virus type 1 (HTLV-1) carriers can develop sufficient humoral immunity after coronavirus disease 2019 (COVID-19) vaccination is unknown. Methods: To investigate humoral immunity after COVID-19 vaccination...
4.
Mitani K, Lee J, Jang J, Tomiyama Y, Miyazaki K, Nagafuji K, et al.
Blood Adv
. 2023 Dec;
8(6):1415-1419.
PMID: 38134300
No abstract available.
5.
Hidaka M, Inokuchi K, Uoshima N, Takahashi N, Yoshida N, Ota S, et al.
Jpn J Clin Oncol
. 2023 Nov;
54(2):153-159.
PMID: 37986553
Objective: Minimal residual disease assessment of BCR-ABL messenger ribonucleic acid levels is crucial in Philadelphia chromosome-positive acute lymphoblastic leukemia for prognosis and treatment planning. However, accurately quantifying minor BCR-ABL transcripts,...
6.
Hiramatsu H, Yokomori R, Shengyi L, Tanaka N, Mori S, Kiyotani K, et al.
Leukemia
. 2023 Oct;
37(12):2502-2506.
PMID: 37864123
No abstract available.
7.
Kameda T, Kataoka K, Kamiunten A, Hidaka M, Miyoshi H, Nakano N, et al.
Haematologica
. 2023 Feb;
108(8):2178-2191.
PMID: 36794502
The prognosis of aggressive adult T-cell leukemia/lymphoma (ATL) is poor, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment. In order to identify favorable prognostic patients after intensive...
8.
Hiramatsu H, Nosaka K, Kusumoto S, Nakano N, Choi I, Yoshimitsu M, et al.
Haematologica
. 2022 Nov;
108(4):1173-1178.
PMID: 36420800
No abstract available.
9.
Rai S, Kim W, Ando K, Choi I, Izutsu K, Tsukamoto N, et al.
Haematologica
. 2022 Oct;
108(3):811-821.
PMID: 36200417
Tucidinostat (formerly known as chidamide) is an orally available, novel benzamide class of histone deacetylase (HDAC) inhibitor that selectively blocks class I and class IIb HDAC. This multicenter phase IIb...
10.
Ishizawa K, Yokoyama M, Kato H, Yamamoto K, Makita M, Ando K, et al.
Cancer Chemother Pharmacol
. 2022 Jul;
90(1):83-95.
PMID: 35796785
Purpose: This phase I/II clinical study was conducted to examine the safety, tolerability, pharmacokinetics, and efficacy of 10-min dosing of bendamustine in patients with previously untreated indolent B-cell non-Hodgkin lymphoma...